Rantes expression is a predictor of survival in stage I lung adenocarcinoma

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3803-3812

  Moran, Christopher J ^a   Arenberg, Douglas A ^a   Huang, Chiang Ching ^b   Giordano, Thomas J ^a   Thomas, Dafydd G ^a   Misek, David E ^a   Chen, Guoan ^a   Iannettoni, Mark D ^a   Orringer, Mark B ^a   Hanash, Samir ^a   Beer, David G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINES, CXC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RANTES; RNA, MESSENGER; SURVIVAL RATE;

EID: 0036900430     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Martin, J., and Rusch, V. Lung neoplasms. In: L. Greenfield, M. Mullholland, K. Oldham, G. Zelenock, and K. Lillemoe (eds.), Surgery: Scientific Principles and Clinical Practice, pp. 1373-1400. Philadelphia: Lippincott Williams and Wilkins, 2001.
2. Mountain, C. F. Lung cancer staging classification. Clin. Chest Med., 14: 43-53, 1993.
3. Slebos, R. J., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J., Wagenaar, S. S., Vanderschueren, R. G., van Zandwijk, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990.
4. Carey, F. A., Prasad, U. S., Walker, W. S., Cameron, E. W., Lamb, D., and Bird, C. C. Prognostic significance of tumor deoxyribonucleic acid content in surgically resected small-cell carcinoma of lung. J. Thorac. Cardiovasc. Surg., 103: 1214-1217, 1992.
5. Harpole, D. H., Richards, W. G., Herndon, J. E., and Sugarbaker, D. J. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg., 61: 1470-1476, 1996.
6. Suzuki, K., Nagai, K., Yoshida, J., Nishimura, M., Takahashi, K., Yokose, T., and Nishiwaki, Y. Conventional clinicopathologic prognostic factors in surgically resected non-small cell lung carcinoma. Cancer (Phila.), 86: 1976-1984, 1999.
7. Johnson, S. K., Kerr, K. M., Chapman, A. D., Kennedy, M. M., King, G., Cockburn, J. S., and Jeffrey, R. R. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer, 27: 27-35, 2000.
8. Pelletier, M. P., Edwardes, M. D., Michel, R. P., Halwani, F., and Morin, J. E. Prognostic markers in respectable non-small cell lung cancer: a multivariate analysis. Can. J. Surg., 44: 180-188, 2001.
9. Hespanhol, V., Queiroga, H., Magalhaes, A., Santos, A. R., Coelho, M., and Marques, A. Survival predictors in advanced non-small lung cancer. Lung Cancer, 13: 253-267, 1995.
10. Fuchs, E. J., and Matzinger, P., Is cancer dangerous to the immune system? Semin. Immunol., 8: 271-280, 1996.
11. Smyth, M. J., Godfrey, D. I., and Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol., 2: 293-299, 2001.
12. Ortegel, J. W., Staren, E. D., Faber, L. P., Warren, W. H., and Braun, D. P. Cytokine biosynthesis by tumor-infiltrating T-lymphocytes from human non-small lung carcinoma. Cancer Immunol. Immunother., 48: 627-634, 2000.
13. Orditura, M., Romano, C., De Vita, F., Galizia, G., Lieto, E., Infusino, S., De Cataldis, G., and Catalano, G. Behavior of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: Relationship with response to therapy and survival. Cancer Immunol. Immunother., 49: 530-536, 2000.
14. Forsberg, G., Ohlsson, L., Brodin, T., Bjork, P., Lando, P. A., Shaw, D., Stern, P. L., and Dohlsten, M. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br. J. Cancer, 85: 129-136, 2001.
15. Moser, B., and Loetscher, P. Lymphocyte traffic control by chemokines. Nat. Immunol., 2: 123-128, 2001.
16. Bless, N. M., Huber-Lang, M., Guo, R., Warner, R. L., Schmal, H., Czermak, B. J., Shanley, T. P., Crouch, L. D., Lentsch, A. B., Sarma, V., Mulligan, M. S., Friedl, H. P., and Ward, P. A. Role of C-C chemokines (macrophage inflammatory protein, monocyte chemoattractant protein-1. RANTES) in acute lung injury in rats. J. Immunol., 164: 2650-2659, 2000.
17. Katoda, J., Mukae, H., Tomono, K., and Kohno, S. High concentrations of β-chemokines in BAL fluid of patients with diffuse panbronchiolitis. Chest, 120: 602-607, 2001.
18. Gerard, C., and Rollins, B. J. Chemokines and disease. Nat. Immunol., 2: 108-115, 2001.
19. Bottazzi, B., Polentarutti, N., Acero, R., Balsari, A., Boraschi, D., Ghezzi, P., Salmona, M., and Mantovani, A. Regulation of the macrophage content of neoplasms by chemoattractants. Science (Wash. DC), 220: 210-221, 1983.
20. Negus, R. P. M., Stamp, G. W. H., Hadley, J., and Balkwill, F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol., 150: 1723-1734, 1997.
21. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., and Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature (Lond.), 410: 50-56, 2001.
22. Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G., and Balkwill, F. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res., 61: 1961-1965, 2001.
23. Mule, J. J., Custer, M., Averbook, B., Yang, J. C., Weber, J. S., Goeddel, D. V., Rosenberg, S. A., and Schall, T. J. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations. Hum. Gen. Ther., 7: 1545-1553, 1996.
24. Luster, A. D., and Leder, P. IP-10 a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med., 178: 1057-1065, 1993.
25. Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Strom, S. R. B., Burdick, M. D., Iannettoni, M. D., and Strieter, R. M. Macrophage infiltration in human non-small-cell lung cancer: The role of C-C chemokines. Cancer Immunol. Immunother., 49: 63-70, 2000.
26. Sharma, S., Stolina, M., Zhu, L., Lin, Y., Batra, R., Huang, M., Strieter, R., and Dubinett, S. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res., 61: 6406-6412, 2001.
27. Giordano, T. J., Shedden, K. A., Schwartz, D. R., Kuick, R., Taylor, J. M., Lee, N., Misek, D. E., Greenson, J. K., Kardia, S. L., Beer, D. G., Rennert, G., Cho, K. R., Gruber, S. B., Fearon, E. R., and Hanash, S. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol., 159: 1231-1238, 2001.
28. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
29. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M. C., Taub, D. T., Iannettoni, M. D., Whyte, R. I., and Strieter, R. M. Interferon-γ-inducible Protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med., 184: 981-992, 1996.
30. Janeway, C. A., Travers, P., Walport, M., and Capra, J. D. Host defense against infection. In: Immunobiology: The Immune System in Health and Disease, pp. 363-415. New York: Current Biology Publication, Garland Publications, 1999.
31. Kaplan, A. Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol., 124: 423-431, 2001.
32. Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., and Lode, H. N. IFN-γ inducible protein-10 is essential for the generation of a protective tumor specific CD8 T-cell response induced by single chain IL-12 gene therapy. J. Immunol., 166: 6944-6951, 2001.
33. Matsukura, S., Kokubu, F., Kubo, H., Tomita, T., Tokunaga, H., Kadokura, M., Yamamoto, T., Kuriowa, Y., Ohno, T., Suzaki, H., and Adachi, M. Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol., 18: 255-264, 1998.
34. Fillion, I., Ouelett, N., Simard, M., Bergeron, Y., Sato, S., and Bergeron, M. G. Role of chemokines and formyl peptides in pneumococcal pneumonia-induced monocyte/macrophage recruitment. J. Immunol., 166: 7353-7361, 2001.
35. Leidal, K. G., Munson, K. L., and Denning, G. M. Small molecular weight secretory factors from Pseudomonas aeruginosa have opposite effects on IL-8 and RANTES expression by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol., 2: 186-195, 2001.
36. Koyama, S., Takamizawa, A., Sato, E., Masubuchi, T., Nagai, S., and Izumi, T. Cyclophosphamide stimulates lung fibroblasts to release neutrophil and monocyte chemoattractants. Am. J. Physiol. Lung Cell Mol. Physiol., 280: L1203-L1211, 2001.
37. Appay, V., and Rowland-Jones, S. L. RANTES: A versatile and controversial chemokine. Trends Immunol., 22: 83-87, 2001.
38. Niwa, Y., Akamatsu, H., Niwa, H., Sumi, H., Ozaki, Y., and Abe, A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res., 7: 285-289, 2001.
39. Asselin-Paturel, C., Echchakir, H., Carayol, G., Gay, F., Opolon, P., Gruenwald, D., Chouaib, S., and Mami-Chouaib, F. Quantative analysis of Th1, Th2 and TGF-β1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer, 77: 7-12, 1998.
40. Huang, M., Wang, J., Lee, P., Sharma, S., Mau, J. T., Meissner, H., Uyemura, K., Modlin, R., Wollman, J., and Dubinett, S. M. Human non-small cell lung cancer cells express a type-2 cytokine pattern. Cancer Res., 55: 3847-3853, 1995.
41. Schall, T. J., Bacon, K., Toy, K. J., and Goeddel, D. V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature (Lond.), 347: 669-671, 1990.
42. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., June, C. H., Regulatory, T. cells from lung cancer patients directly inhibit autologous T-cell proliferation. J. Immunol., 168: 4272-4276, 2002.
43. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J., and Meyerson, M., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA, 98: 13790-13795, 2001.
44. Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G. D., Perou, C. M., Whyte, R. I., Altman, R. B., Brown, P. O., Botstein, D., and Petersen, I. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA, 98: 13784-13789, 2001.
45. Beer, D. G., Kardia, S. L. R., Huang, C-C, Giordano, T. J., Levin, A. L., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M. G., Iannettoni, M. D., Orringer, M. B., and Hanash, S. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med., 8: 816-824, 2002.